Tokyo, Japan and Cambridge, UK, 14 February 2023 – Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development, provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2022. The full report can be found here.
Chris Cargill, President & CEO of Sosei Heptares, commented: “2022 was a very important and successful year for Sosei Heptares as our newly appointed leadership team set about evolving and implementing a clear strategy to accelerate the growth and development of the Company. This strategy is based on four key pillars: (1) to extend and enhance the competitive advantages of our in-house GPCR drug discovery platform through internal innovation and collaboration; (2) to drive forward existing partnerships with global biopharma companies and initiate new high-value partnerships to ensure the continued flow of revenues; (3) to transform how we do R&D through a more focused, program-centric operational model that leverages enhanced translational medicine capabilities to improve productivity, value and success; and (4) to build out an agile, scalable and effective clinical development and commercialization business in Japan to deliver new medicines to patients in this market.
“Overall, the progress we have made in 2022 has been exceptional and I would like to thank the teams in Japan and in the UK for their dedication and hard work. We enter 2023 well positioned and well financed to progress our strategy across all areas, and with a clear vision to build a disruptive commercial-stage biopharmaceutical company making a difference for patients worldwide.”
Operational Highlights for Q4 2022
Operational Highlights for Full Year 2022
Financial Highlights for the 12-month Period ended 31 December 2022
*Convenience conversion to US$ at the following rates: FY 2022: 1US$ =131.30 JPY; FY 2021: 1US$ =110.16 JPY; 31 Dec 2022: 1US$ = 131.27 JPY; 31 Dec 2021: 1US$ = 115.08 JPY
** Core operating profit / loss is an alternative performance measure which adjusts for material non-cash costs and one-off costs in order to provide insights into the recurring cash generation capability of the core business.